Inventor · disambiguated record
Robert Louis Hoffman
Also filed as: HOFFMAN ROBERT L · HOFFMAN ROBERT LOUIS
32 granted patents·19 pending applications·429 citations·filing 1998–2024
97Inventor score
Top patents by PatentIndex Score
51 records- 0197US11014911B2CDK2 inhibitorsPFIZER·Filed 2020·Granted May 25, 2021·11 cites·4 claims
- 0297US6992087B2Substituted aryl 1,4-pyrazine derivativesPFIZER·Filed 2002·Granted Jan 31, 2006·68 cites·20 claims
- 0396US11795173B1Substituted pyridines as PARP1 inhibitorsXINTHERA INC·Filed 2023·Granted Oct 24, 2023·5 cites·18 claims
- 0496US6849640B2Therapeutic 1H-pyrido [4,3-b] indolesUPJOHN CO·Filed 2002·Granted Feb 1, 2005·113 cites·38 claims
- 0595US12006322B2Substituted pyridines as PARP1 inhibitorsXINTHERA INC·Filed 2023·Granted Jun 11, 2024·2 cites·4 claims
- 0695US11718603B2CDK2 inhibitorsPFIZER·Filed 2021·Granted Aug 8, 2023·3 cites·21 claims
- 0795US11680056B2MK2 inhibitors and uses thereofXINTHERA INC·Filed 2022·Granted Jun 20, 2023·3 cites·28 claims
- 0895US8680111B2Macrocyclic derivatives for the treatment of diseasesPFIZER·Filed 2013·Granted Mar 25, 2014·54 cites·18 claims
- 0994US11802128B2Azetidine and pyrrolidine PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Oct 31, 2023·3 cites·15 claims
- 1094US11685719B2Pyridinone MK2 inhibitors and uses thereofXINTHERA INC·Filed 2022·Granted Jun 27, 2023·3 cites·30 claims
- 1194US7041672B2Substituted aryl 1, 4-pyrazine derivativesPFIZER·Filed 2004·Granted May 9, 2006·59 cites·25 claims
- 1293US11939329B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Mar 26, 2024·2 cites·5 claims
- 1393US11773082B2CDK2 inhibitorsPFIZER·Filed 2021·Granted Oct 3, 2023·2 cites·25 claims
- 1493US10233188B2CDK2/4/6 inhibitorsPFIZER·Filed 2017·Granted Mar 19, 2019·13 cites·2 claims
- 1590US6313307B1Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic ringsUPJOHN CO·Filed 2000·Granted Nov 6, 2001·18 cites·6 claims
- 1689US9133215B2Macrocyclic derivatives for the treatment of diseasesPFIZER·Filed 2014·Granted Sep 15, 2015·16 cites·18 claims
- 1785US12421241B2Substituted pyridines as PARP1 inhibitorsXINTHERA INC·Filed 2024·Granted Sep 23, 2025·0 cites·4 claims
- 1885US6166056APhenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic ringsPHARMACIA IND·Filed 1998·Granted Dec 26, 2000·24 cites·13 claims
- 1982US11987574B2MK2 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted May 21, 2024·0 cites·22 claims
- 2081US2024294506A1Cdk2 inhibitorsPFIZER·Filed 2023·Application pending·0 cites
- 2179US12384780B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2024·Granted Aug 12, 2025·0 cites·2 claims
- 2279US10125130B2Cycloalkyl-linked diheterocycle derivativesPFIZER·Filed 2017·Granted Nov 13, 2018·2 cites·21 claims
- 2377US12139462B2Pyridinone MK2 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Nov 12, 2024·0 cites·30 claims
- 2475US6734301B22,3,4,5-Tetrahydro-1H-[1,4]diazepino[1,7-a]indole compoundsUPJOHN CO·Filed 2001·Granted May 11, 2004·15 cites·8 claims
- 2575US2022324872A1CDK2/4/6 InhibitorsPFIZER·Filed 2022·Application pending·0 cites
- 2674US7087617B2Substituted pyrimidine derivativesPFIZER·Filed 2004·Granted Aug 8, 2006·6 cites·5 claims
- 2773US10676471B2Cycloalkyl-linked diheterocycle derivativesPFIZER·Filed 2019·Granted Jun 9, 2020·0 cites·2 claims
- 2869US6964965B2Substituted pyrazine derivativesPHARMACIA & UPJOHN·Filed 2003·Granted Nov 15, 2005·4 cites·24 claims
- 2969US2023159525A1Azetidine and pyrrolidine parp1 inhibitors and uses thereofXINTHERA INC·Filed 2022·Application pending·0 cites
- 3068US7015229B2Substituted pyrimidinones and pyrimidinthionesPFIZER·Filed 2003·Granted Mar 21, 2006·3 cites·21 claims
- 3168US2025129051A1Parp1 inhibitors and uses thereofGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 3268US2023128041A1Parp1 inhibitors and uses thereofXINTHERA INC·Filed 2022·Application pending·0 cites
- 3367US11396512B2CDK2/4/6 inhibitorsPFIZER·Filed 2020·Granted Jul 26, 2022·0 cites·12 claims
- 3467US10800783B2CDK2/4/6 inhibitorsPFIZER·Filed 2019·Granted Oct 13, 2020·0 cites·16 claims
- 3565US2024279214A1Alpha4 beta7 inegrin antagonists and uses thereofXINTHERA INC·Filed 2023·Application pending·0 cites
- 3663US2024182449A1Crystalline forms of an mk2 inhibitorXINTHERA INC·Filed 2023·Application pending·0 cites
- 3762US2024174669A1Crystalline forms of a parp1 inhibitorXINTHERA INC·Filed 2023·Application pending·0 cites
- 3862US2025171418A1Parp1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Application pending·0 cites
- 3958US2019040055A1Cycloalkyl-Linked Diheterocycle DerivativesPFIZER·Filed 2018·Application pending·0 cites
- 4056US2005054683A1Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic ringsFiled 2003·Application pending·0 cites
- 4154US12485157B2Method of treating COVID-19PFIZER·Filed 2021·Granted Dec 2, 2025·0 cites·21 claims
- 4252US2006217398A1Substituted pyrimidine derivativesPFIZER·Filed 2006·Application pending·0 cites
- 4350US11926642B2Compounds and methods for the treatment of COVID-19PFIZER·Filed 2021·Granted Mar 12, 2024·0 cites·19 claims
- 4448US2017050958A1Cycloalkyl-Linked Diheterocycle DerivativesPFIZER·Filed 2015·Application pending·0 cites
- 4547US7250418B2Compounds as CRF1 receptor antagonistsPFIZER·Filed 2004·Granted Jul 31, 2007·0 cites·12 claims
- 4647US2005143403A1Substituted pyrimidinones and pyrimidinthionesPFIZER·Filed 2004·Application pending·0 cites
- 4746US2005020601A1Novel pyrazinones as CRF1 receptor antagonistsPFIZER·Filed 2004·Application pending·0 cites
- 4844US2004116444A1Substituted 1,4-pyrazine derivativesFiled 2003·Application pending·0 cites
- 4943US2023157998A1Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019PFIZER·Filed 2021·Application pending·0 cites
- 5042US2004209870A1Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compoundsFiled 2004·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Robert Louis Hoffman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →